WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H561700
CAS#: 144034-80-0
Description: Rizatriptan is a serotonin-1b and serotonin-1d receptor agonist.
Hodoodo Cat#: H561700
Name: Rizatriptan
CAS#: 144034-80-0
Chemical Formula: C15H19N5
Exact Mass: 269.16
Molecular Weight: 269.350
Elemental Analysis: C, 66.89; H, 7.11; N, 26.00
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Rizatriptan; Risatriptan; MK 462 free base;
IUPAC/Chemical Name: 2-(5-((1H-1,2,4-Triazol-1-yl)methyl)-1H-indol-3-yl)-N,N-dimethylethanamine
InChi Key: ULFRLSNUDGIQQP-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3
SMILES Code: CN(C)CCC1=CNC2=C1C=C(CN3N=CN=C3)C=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 269.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Tradtrantip L, Jin BJ, Yao X, Anderson MO, Verkman AS. Aquaporin-Targeted Therapeutics: State-of-the-Field. Adv Exp Med Biol. 2017;969:239-250. doi: 10.1007/978-94-024-1057-0_16. Review. PubMed PMID: 28258578; PubMed Central PMCID: PMC5628614.
2: Maasumi K, Tepper SJ, Kriegler JS. Menstrual Migraine and Treatment Options: Review. Headache. 2017 Feb;57(2):194-208. doi: 10.1111/head.12978. Epub 2016 Dec 2. Review. PubMed PMID: 27910087.
3: Allais G, Benedetto C. Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine. Drug Des Devel Ther. 2016 Oct 3;10:3225-3236. eCollection 2016. Review. PubMed PMID: 27757013; PubMed Central PMCID: PMC5055118.
4: Capi M, Curto M, Lionetto L, de Andrés F, Gentile G, Negro A, Martelletti P. Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Ther Adv Neurol Disord. 2016 Sep;9(5):414-23. doi: 10.1177/1756285616650619. Epub 2016 Jun 3. Review. PubMed PMID: 27582896; PubMed Central PMCID: PMC4994780.
5: Kacperski J, Hershey AD. Newly Approved Agents for the Treatment and Prevention of Pediatric Migraine. CNS Drugs. 2016 Sep;30(9):837-44. doi: 10.1007/s40263-016-0375-y. Review. PubMed PMID: 27503180.
6: Kassem AA. Formulation Approaches of Triptans for Management of Migraine. Curr Drug Deliv. 2016;13(6):882-98. Review. PubMed PMID: 27109335.
7: Richer L, Billinghurst L, Linsdell MA, Russell K, Vandermeer B, Crumley ET, Durec T, Klassen TP, Hartling L. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst Rev. 2016 Apr 19;4:CD005220. doi: 10.1002/14651858.CD005220.pub2. Review. PubMed PMID: 27091010.
8: Patniyot IR, Gelfand AA. Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review. Headache. 2016 Jan;56(1):49-70. doi: 10.1111/head.12746. Review. PubMed PMID: 26790849.
9: Becker WJ. Acute Migraine Treatment. Continuum (Minneap Minn). 2015 Aug;21(4 Headache):953-72. doi: 10.1212/CON.0000000000000192. Review. PubMed PMID: 26252584.
10: Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, Peterson J, Coyle D, Skidmore B, Gomes T, Clifford T, Wells G. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015 Jul-Aug;55 Suppl 4:221-35. doi: 10.1111/head.12601. Epub 2015 Jul 14. Review. PubMed PMID: 26178694.
11: Becker WJ. Acute Migraine Treatment in Adults. Headache. 2015 Jun;55(6):778-93. doi: 10.1111/head.12550. Epub 2015 Apr 15. Review. PubMed PMID: 25877672.
12: Sakai F. Oral triptans in children and adolescents: an update. Curr Pain Headache Rep. 2015 Mar;19(3):8. doi: 10.1007/s11916-015-0478-z. Review. PubMed PMID: 25754598.
13: Bhambri R, Mardekian J, Liu LZ, Schweizer E, Ramos E. A review of the pharmacoeconomics of eletriptan for the acute treatment of migraine. Int J Gen Med. 2015 Jan 12;8:27-36. doi: 10.2147/IJGM.S73673. eCollection 2015. Review. PubMed PMID: 25624770; PubMed Central PMCID: PMC4296958.
14: Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499. Review. PubMed PMID: 25600718.
15: Obermann M, Strupp M. Current treatment options in vestibular migraine. Front Neurol. 2014 Dec 4;5:257. doi: 10.3389/fneur.2014.00257. eCollection 2014. Review. PubMed PMID: 25538676; PubMed Central PMCID: PMC4255594.
16: Saracco MG, Allais G, Tullo V, Zava D, Pezzola D, Reggiardo G, Omboni S, Benedetto C, Bussone G, Aguggia M. Efficacy of frovatriptan and other triptans in the treatment of acute migraine of normal weight and obese subjects: a review of randomized studies. Neurol Sci. 2014 May;35 Suppl 1:115-9. doi: 10.1007/s10072-014-1752-2. Review. PubMed PMID: 24867847.
17: Franconi F, Finocchi C, Allais G, Omboni S, Tullo V, Campesi I, Reggiardo G, Benedetto C, Bussone G. Gender and triptan efficacy: a pooled analysis of three double-blind, randomized, crossover, multicenter, Italian studies comparing frovatriptan vs. other triptans. Neurol Sci. 2014 May;35 Suppl 1:99-105. doi: 10.1007/s10072-014-1750-4. Review. PubMed PMID: 24867845; PubMed Central PMCID: PMC4035544.
18: Belvis R, Mas N, Aceituno A. Migraine attack treatment : a tailor-made suit, not one size fits all. Recent Pat CNS Drug Discov. 2014 Apr;9(1):26-40. Review. PubMed PMID: 24605940.
19: Cui XP, Ye JX, Lin H, Mu JS, Lin M. Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis. Pain Pract. 2015 Feb;15(2):124-31. doi: 10.1111/papr.12158. Epub 2013 Dec 30. Review. PubMed PMID: 24382126.
20: Ramón-Carbajo C, Alvarez-Escudero R, Pascual J. [Rizatriptan: experience after 15 years of clinical use]. Rev Neurol. 2013 Dec 16;57(12):549-55. Review. Spanish. PubMed PMID: 24288104.
